Questions discussed in this category
Tumor felt to be technically unresectable due to extensive cervical/parametrial involvement.
ER/PR and HER2 testing are pending.
73yo, tumor traverses the myometrium to focally involve the serosa. 1/6 sentinels with ITC and the rest negative.
Patient has tolerated combination therapy well to date.
Pt is 73yo, Grade 1, 81% invasion, MELF like features, foci of LVSI, and 47 ITCs identified.
Pt is 69yo, tumor 1.4cm, negative LVSI, ER/PR +
If patient meets high intermediate risk criteria, would you consider chemotherapy in addition to radiation?
Does not technically meet high intermediate risk criteria.
VC brachy, pelvic RT, +/- chemo?
Does your management change if it is confined to the endometrium without myometrium invasion or if it is only ...
In the unfortunate setting where you cannot get an underinsured patient whose policy does not cover radiotherapy started on treatment without guarante...
Would you consider adjuvant chemotherapy, radiation therapy, hormone therapy, or surveillance?
Do you give cuff and chemo or pelvic CRT or chemo alone?
The patient has a history of pelvic radiation and progressed through first line carboplatin/taxol. She has had a partial response to pembro/lenvatinib...
Would you consider "neoadjuvant" hormonal therapy to shrink tumors and potentially make more amenable to complete cytoreduction at a later date?
Woul...
Incidental diagnosis after hysterectomy
This case involves an impressive ‘high volume’ vaginal recurrence and patient was not originally planned for adjuvant therapy. Concerned t...
Would you offer EBRT alone or EBRT with vaginal cuff brachytherapy after surgery and chemotherapy for stage III (T3N0) carcinosarcoma of the uterus?
...
Does residual grade 1-2 neuropathy from Taxol/ carbo 10 years ago affect your recommendation?
Ie for patients who are inoperable due to comorbidities?
For a patient with good response to immunotherapy (unable to receive chemotherapy due to kidney function, comorbidities) where previously avid LN have...
Since no data exists or is pending, and the two disease processes are similar, should we consider PARP inhibition in this setting? This is assumi...
http://abstracts.asco.org/199/AbstView_199_180760.html
http://abstracts.asco.org/199/AbstView_199_187537.html
Does the GOG 249 abstract guide you one way or the other?
How do you counsel a pre-menopausal female with endometrioid cancer desiring definitive RT with egg harvesting and IVF for fertility preservation inst...
No adjuvant treatment was given upfront
Insurance authorization for protons is pending, but if the patient cannot have protons would you treat with standard fractionation to ~70Gy or conside...
NCCN recommends brachytherapy plus or minus pelvic RT for surgically staged Grade 1, Stage II patients, but these originally staged IIB patients were ...
Would you consider EBRT or brachytherapy boost to the nodes? what dose would you recommend?
For the management of stage II endometrial cancer, NCCN says pelvic RT and/or vaginal brachytherapy. Do you ever add vaginal cuff boost to pelv...
If so, would you treat the whole pelvis, cuff brachytherapy, or both?
MRI and cervical biopsy are negative for cervical involvement
Would estrogen cream be helpful in this scenario?
are there any positive or negative synergies from combined megestrol/RT treatment?
At what point would you introduce the discussion of weight management, whether for risk reduction or overall health?
The NCCN recommends either systemic therapy + brachytherapy or pelvic RT + brachy or brachy alone or observation. How do you decide among these option...
The disease involving the endocervix was felt to be separate and appeared like a drop metastases
Given the recent press release regarding the update on the phase 3 soft tissue sarcoma study of LARTRUVO (olaratumab) showing no benefit to the combin...
Female in her 60s who had presented originally with well-differentiated endometrioid adeno clinically and radiographically involving bilateral paramet...
For a woman with complete resection of serous intraepithelial carcinoma of the endometrium, would you recommend adjuvant radiation or chemotherapy? Wh...
Current NCCN guidelines suggest that vaginal brachytherapy is optional, and there may be concern for over-treatment locally given competing risk of di...
In what situations is it appropriate to offer observation (rather than VBT) to patients with stage II endometrial carcinoma who have had a radical hys...
Would you approach this situation as synchronous primaries (eg. FIGO IA in both) or as a locally advanced endometrial cancer (FIGO IIIA)?
What adjuva...
For example, in an otherwise intermediate risk localized endometrial cancer (Grade 2, FIGO IB)?
What clinicopathologic features do you typically consider?
If the post-operative simulation films reveal a significant lymphocele secondary to pelvic lymph node sampling, is it imperative that the entire lymph...
The gyn oncs at my institution sometimes will not perform lymphadenectomy if biopsy indicates low risk disease. Would LVSI as sole adverse risk factor...
Is there any indication for ENI in early stage disease or in advanced stages, without pathologic confirmation or PET positivity or CT size criteria?
What exactly do you contour and what is your dose constraint to that volume?
Does using something like a vienna applicator allow you to avoid dose escalation with more external beam? How do you recommend doing a classic pa...
Some classic references recommend the coverage of the entirety of the sacrum but the volume delineation guidelines for both seem to only cover the mos...
Does hydroureter and leg edema alter your opinion?
Brachytherapy, EBRT or both and what is the best dose?
927187459172902890448994887288888240832888138801395851285158019840184058402839051079401629810880697973788178677863788478417770773377587334769177276440317253247498751275067416475820786126930702158306955693868436820653265916543648610463156271624661781002611960526007598557905352556953965329503426948354736477745674670462744304392440443094168406922782211214121502030889859428701553515486424426425268270388380326
Papers discussed in this category
Gynecologic oncology, 2004-03
Int. J. Radiat. Oncol. Biol. Phys., 2005-08-01
Int. J. Radiat. Oncol. Biol. Phys., 1990-02-01
Gynecologic oncology, 2003-12
Int. J. Radiat. Oncol. Biol. Phys., 2014-05-01
Brachytherapy, 2015
Gynecologic oncology, 2007-11
Eur. J. Cancer, 2008 Apr 02
J Clin Oncol,
Gynecologic oncology, 2018-10
Gynecologic oncology, 2014-11
Lancet, 2010-03-06
International journal of radiation oncology, biology, physics, 2018-08-01
Brachytherapy, 2019 Sep - Oct
Gynecologic oncology, 2009-10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-01-01
Gynecologic oncology, 2013-10
Gynecologic oncology, 2013-01
Eur. J. Cancer, 2010 Jul 07
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-07-20
The New England journal of medicine, 2019-06-13
Lancet Oncol., 2019 Jul 22
Gynecol Oncol, 2019 Sep
Cancer Nurs, 2017-04-21
American journal of clinical oncology, 2018-08
Cancer, 1987-10-15
Gynecologic oncology, 2015-09
Brachytherapy, 2016 Nov - Dec
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2014-10
Practical radiation oncology, 2017
Gynecologic oncology, 2018-08
International journal of radiation oncology, biology, physics, 2017-04-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-07-10
Gynecol Oncol, 2017 Aug
J Gynecol Oncol, 2015 Nov 23
Int J Gynaecol Obstet,
Int J Womens Health, 2017 May 02
Radiat Oncol, 2015 Feb 22
Obstet Gynecol,
Annals of surgical oncology, 2016-05
Obstetrics and gynecology, 2013-09
Lancet Oncol.,
Gynecol. Oncol., 2005 Dec 20
International journal of radiation oncology, biology, physics, 2014-03-15
Brachytherapy, 2015
Nature, 2013-05-02
Gynecologic oncology, 2019-09
F1000Res, 2019 Jun 12
Lancet Oncol., 2018 Feb 12
Lancet, 2019 Apr 11
Gynecologic oncology, 2001-10
Int. J. Gynecol. Pathol.,
Gynecol. Oncol., 2019 Sep 26
JAMA oncology, 2016-11-01
Gynecologic oncology, 2013-04
Lancet, 2008 Dec 16
J. Natl. Cancer Inst., 2008 Nov 25
Gynecologic oncology, 2009-10
Am J Obstet Gynecol, 2017 Dec 06
Journal of minimally invasive gynecology, 2016-02-01
Am J Obstet Gynecol, 2020 Jul 18
The Lancet. Oncology, 2017-03
International journal of radiation oncology, biology, physics, 2004-03-01
Gynecologic oncology, 2015-11
Gynecol Oncol, 2020 May 29
Cancer, 2017-03-01
Lancet Oncol, 2019 Mar 25
Gynecologic oncology, 2007-06
Int J Gynecol Cancer,
Lancet,
Gynecol Oncol Rep, 2020 Jan 30
World J Surg Oncol, 2017 Jan 10
Gynecologic oncology, 2012-10
Practical radiation oncology, 2019
Brachytherapy, 2019 Apr 17